Please ensure Javascript is enabled for purposes of website accessibility

Abbvie's HIV Drug Kaletra Fails to Help COVID-19 Patients

By Brian Orelli, PhD - Mar 19, 2020 at 2:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A subset of patients improved faster, but further clinical trials are required to see if the results are real.

The coronavirus that causes COVID-19 and HIV are both RNA-based viruses, so there was hope that current HIV medications might be able to speed recovery of patients with COVID-19. Unfortunately, early evidence suggests that just isn't the case.

On Monday, Johnson & Johnson (JNJ 1.46%) said there was no evidence that its HIV drug Prezista, by itself or in combination with other HIV drugs, has any effect against SARS-CoV-2, the virus that causes COVID-19.

And on Wednesday, doctors in China published an article in The New England Journal of Medicine reporting that AbbVie's (ABBV 1.93%) HIV drug Kaletra plus standard of care wasn't any better than the standard of care.

In the clinical trial, which enrolled 199 patients, treatment with Kaletra for two weeks didn't improve survival, the amount of virus in the patients, or even the length of time that patients stayed in the hospital.

Doctors in protective suits and a patient in a restricted area

Image source: Getty Images.

The patients in the trial were severely ill; the mortality rate of 22.1% was higher than the mortality rate found in other studies, which could have skewed the results. When excluding three patients who died early in the study, the median time to clinical improvement was better for patients treated with Kaletra (15 days vs. 16 days).

Kaletra also appeared to improve recovery and mortality in patients who were treated within 12 days of onset of COVID-19 symptoms, although the analysis was after the fact and not built into the study. "These observations are hypothesis-generating and require additional studies to determine whether [Kaletra] treatment given at a certain stage of illness can reduce some complications in COVID-19," the authors of the study noted.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
$182.29 (1.46%) $2.63
AbbVie Inc. Stock Quote
AbbVie Inc.
$152.34 (1.93%) $2.89

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.